Customer Experience Representative

SNDL Inc reported Q2 2026 results on 28 July, showing mixed performance amid market challenges. Net revenue declined 3.7% year over year to CAD 235.8 million, whilst gross profit fell 16.6% with margins down 3.7 percentage points. The Canadian cannabis and liquor retailer posted an operating loss of CAD 7.8 million. However, the company generated positive operating cash flow and improved free cash flow by CAD 1.2 million year over year. SNDL maintained a debt-free balance sheet with CAD 183.2 million in unrestricted cash. The firm repurchased 11.7 million shares during the quarter. CEO Zach George attributed 80-90% of margin pressure to production ramp-up costs at its Jeter facility. The company expects its pending restructuring to provide exposure to US medical cannabis operations, potentially lifting annual revenue above CAD 1 billion.

SNDL completes Parallel asset acquisition, expands U.S. medical cannabis footprint. | / | Jonathon Brown, The Market Link 0 Comments| 3 hours ago | + Favorites * SNDL (CSE:SNDL) completed its acquisition of key Parallel cannabis assets, gaining indirect control of operations across Florida, Texas, and Massachusetts * The deal eliminates approximately US$842 million of Parallel debt and gives SNDL exposure to a platform generating about US$150 million in annualized revenue * SNDL also reported second-quarter 2026 revenue of C$235.8 million, with lower sales and margins contributing to an operating loss of C$7.8 million * SNDL stock (CSE:SNDL) opened trading at C$1.83 SNDL Inc. (CSE:SNDL) announced the completion of its acquisition of certain assets from Surterra Holdings Inc. and affiliated entities, collectively known as Parallel. The transaction provides SNDL with significant exposure to U.S. medical cannabis operations in Florida, Texas, and Massachusetts while positioning the company for potential future consolidation of those assets under its corporate structure. The acquisition was completed through a strict foreclosure process involving Parallel, its subsidiaries, creditors, and CDXX TransCo LLC. As part of the restructuring, specified equity interests and assets tied to Parallel's operations were transferred to TransactionCo. SNDL, through its Sunstream Bancorp Inc. joint venture, now holds an indirect majority economic interest equivalent to 66.7 per cent of TransactionCo's equity and 69.4 per cent of its debt. This article is a journalistic opinion piece that has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice. SNDL stated that it expects to convert its indirect economic exposure into direct, consolidated holdings in the coming months, subject to legal, regulatory, accounting, and NASDAQ requirements. If completed, the move would position SNDL among the first NASDAQ-listed companies with direct, consolidated exposure to U.S. medical cannabis businesses. The company noted that any adult-use cannabis operations, including those in Massachusetts, are expected to remain deconsolidated unless future regulatory and accounting conditions allow for a different treatment. Multi-state cannabis platform. The acquired assets include 56 retail locations and three cultivation and manufacturing facilities across three states. SNDL said the platform generates approximately US$150 million in annualized revenue and provides a foundation for future growth initiatives. In Florida, the business operates 43 dispensaries under the Surterra Wellness brand, supported by a cultivation and production facility spanning approximately 175,000 square feet. Florida remains one of the largest medical cannabis markets in the United States. The Texas operations include 10 retail and pickup locations operating under the Goodblend brand. The business is supported by a cultivation and production facility and is one of only three active licensed operators serving Texas' population of approximately 31.7 million residents. Industry observers continue to view Texas as a potentially significant long-term growth market due to its large population and evolving medical cannabis program. In Massachusetts, the acquired portfolio includes three dispensaries operating under the New England Treatment Access (NETA) brand and a cultivation and production facility encompassing roughly 19,600 square feet. "SNDL now supports a 249-store cannabis retail network, the largest in the world by store count," the company's CEO, Zach George, said in a news release. "We believe that the operating discipline, retail expertise and lessons learned from Canada's intensely competitive cannabis market - including navigating regulatory complexity and excessive tax rates - will serve us well as we expand in key U.S. medical cannabis markets such as Florida, Massachusetts, and Texas." Debt restructuring and foreclosure process. The transaction marks the culmination of a restructuring effort that began after Parallel defaulted on a US$150 million secured loan originally provided by Talladega LP, a partnership wholly owned by affiliates of Sunstream, in May 2021. Following the default, Talladega and a group of senior noteholders supplied additional financing intended to preserve the value of the business while Parallel evaluated strategic alternatives. According to SNDL, an extensive marketing process failed to produce an acceptable third-party transaction, leading stakeholders to pursue the foreclosure-based restructuring that was finalized this week. As part of the transaction, creditor claims were converted into a mix of newly issued debt and ownership interests in TransactionCo and its subsidiaries. SNDL said the restructuring eliminated approximately US$842 million in Parallel debt obligations, significantly reducing leverage and creating what it described as a more sustainable capital structure for the business moving forward. Second-quarter results reflect challenging market conditions. The acquisition announcement coincided with SNDL's release of its second-quarter 2026 financial and operational results. For the quarter, net revenue totalled C$235.8 million, down 3.7 per cent compared with the same period a year earlier. The company attributed the decline primarily to ongoing market pressures affecting both its liquor and cannabis businesses. Gross profit was C$56.3 million, a decrease of 16.6 per cent from the prior-year period. Gross margin declined to 23.9 per cent, down 3.7 percentage points year over year. SNDL cited lower revenue across multiple business segments as well as production ramp-up costs associated with Jeeter-branded cannabis products. The company reported an operating loss of C$7.8 million during the quarter, an increase from the prior year. Management pointed to weaker liquor retail performance, Jeeter-related production costs, lower valuations in equity-accounted investments, and the absence of a prior-year impairment reversal as contributing factors. Adjusted operating loss, excluding restructuring-related charges, totalled C$7.0 million. "While these near-term factors pressured revenue and operating income, we remain focused on disciplined execution, cost optimization, and the strategic initiatives that we believe will strengthen SNDL's competitive position over time," George stated in a media release. "Importantly, we continued to generate positive operating cash flow, improved free cash flow compared to the prior year, and maintained a debt-free balance sheet with strong liquidity." Cash flow for the quarter was negative C$30.2 million, with SNDL noting that C$23.5 million of cash outflows were related to share repurchases. Free cash flow was negative C$6.7 million but improved by C$1.2 million compared with the same quarter in 2025. Business significance. The completion of the Parallel transaction represents one of SNDL's most significant moves into the U.S. cannabis market to date. By obtaining control over a large multi-state medical cannabis platform while significantly reducing Parallel's debt burden, SNDL gains exposure to established operations in three regulated markets. The company now faces the next stage of integrating and potentially consolidating these assets while navigating NASDAQ listing requirements and evolving cannabis regulations in the United States. Investors will be watching closely to see whether the transaction can strengthen SNDL's long-term growth prospects despite continued near-term pressure on revenue, margins, and profitability. SNDL Inc. engages in the production, distribution, and sale of cannabis products for the adult-use market in Canada and internationally. SNDL stock (CSE:SNDL) opened trading more than 5 per cent lower at C$1.83 and has lost more than 20 per cent since the year began. Join the discussion: Find out what the Bullboards are saying about SNDL and check out Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here. + Favorites Follow STOCKHOUSE Today Featured company. Grizzly Discoveries Expands Large Copper-Gold Porphyry Target at Sappho | Grizzly Discoveries (TSXV: GZD) Play Episode MustGrow Biologics Expands U.S. Reach as Demand Outpaces Supply | MustGrow Biologics (TSXV: MRGO) HotCopper Wire #52 A big, juicy gold megamerger